| Name | Title | Contact Details |
|---|---|---|
James Desiderio |
Sr. Vice President, Regulatory Affairs and Quality | Profile |
Adam Veness |
Vice President, General Counsel and Secretary | Profile |
Adam Veness |
Senior Vice President, General Counsel and Secretary | Profile |
Adam Davey |
Associate Director, Corporate Counsel | Profile |
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).
DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Saskatchewan Research Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.